G Sachs Provides ST Risk Assessment for Three Firm Types as US Expected to Increase Scrutiny on CN Innovative Drugs, Potentially Creating 'Headline Risks' for CN Pharmaceutical Companies
Trump Administration's Drug Policy Discussion: Goldman Sachs reported that the Trump administration is considering restrictions on Chinese pharmaceuticals and drafting an executive order to limit the entry of innovative Chinese drugs into the US market, although a White House spokesperson stated that the government is not actively pursuing this draft at the moment.
Impact on Chinese Biotech Sector: Goldman Sachs believes that potential restrictions could create "headline risks" for the Chinese biotech and pharmaceutical sector, leading to increased stock price volatility, especially as major US pharmaceutical companies lobby against the proposed order.
Categorization of Chinese Biotech Companies: The report categorizes Chinese biotech firms into three groups based on their global presence and partnerships, with varying levels of expected impact from the potential restrictions.
Market Reactions and Short Selling Data: The article includes specific stock performance and short selling data for various companies within the categorized groups, indicating market sentiment and potential risks associated with the evolving regulatory landscape.
Trade with 70% Backtested Accuracy
Analyst Views on 01093
About the author


Market Performance: The Hang Seng Index (HSI) rose by 468 points (1.9%) to 25,789, while the Hang Seng Tech Index (HSTI) increased by 177 points (3.7%) to 4,973, and the Hang Seng China Enterprises Index (HSCEI) gained 187 points (2.2%) to 8,638.
Top Gainers: Notable stock performances included JD Logistics, which surged 21.3%, JD up 8.5%, and Trip.com rising 7.0%. Major companies like Xiaomi, Alibaba, and Tencent also saw significant increases in their stock prices.
Short Selling Activity: High short selling volumes were reported for several stocks, with Alibaba and JD having short selling ratios of 16.072% and 50.972%, respectively, indicating investor caution despite their price increases.
Other Notable Movements: Stocks like TransThera and Bayzed Health experienced substantial gains of 34.9% and 21.5%, respectively, while Chinahongqiao saw a decline of 3.3%, reflecting varied performance across different sectors.

Market Performance: The Hang Seng Index (HSI) fell by 291 points (1.1%) to close at 25,768, with a total market turnover of $370.55 billion.
Active Heavyweights: Major stocks like Xiaomi, Meituan, and Alibaba experienced declines, with Xiaomi dropping 4.7% and Meituan down 2.3%.
Notable Movers: Xinyi Solar and Zijin Mining saw significant losses, with Xinyi Solar down 6.3% and Zijin Mining down 6.1%, while ENN Energy and PetroChina gained 5.1% and 5%, respectively.
Short Selling Trends: High short selling ratios were observed in several stocks, including Ping An at 27% and BYD Electronic at 28.6%, indicating increased bearish sentiment among investors.

Market Performance: The Hang Seng Index (HSI) fell by 74 points (0.3%) to 25,985, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.
Active Heavyweights: Notable stock movements included Xiaomi and Meituan, which saw declines of 3% and 1.2% respectively, while Tencent and Alibaba experienced slight gains.
Significant Declines: Xinyi Solar, Pop Mart, and XPeng faced substantial drops, with declines of 5.4%, 4.7%, and 4.6% respectively, indicating a challenging day for these companies.
Top Gainers: Companies like PetroChina and CNOOC saw positive movements, with PetroChina rising 4% to a new high, while other stocks like Hao Tian International and Zhongyu Energy experienced significant increases.

Market Performance: The Hang Seng Index (HSI) fell by 420 points (1.6%) to 26,209, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.1% and 1.4%, respectively.
Active Heavyweights: Major stocks like Xiaomi, Meituan, and Alibaba saw significant drops, with Xiaomi down 4.6% and Alibaba down 2.7%, amidst high short selling activity.
Notable Movers: Xinyi Glass and CNOOC were standout performers, with Xinyi Glass rising 11.4% to a new high, while several other stocks, including Sunny Optical and HSBC Holdings, faced declines.
Short Selling Trends: The short selling ratios for various stocks were notable, with JD Health and HSBC Holdings showing high short selling activity, indicating bearish sentiment among investors.

Market Performance: The Hang Seng Index (HSI) rose by 249 points (0.9%) to close at 26,630, with a total market turnover of $288.42 billion.
Active Heavyweights: Notable stock movements included TENCENT (+1.2%), MEITUAN (+0.9%), and HKEX (+0.9%), while XIAOMI (-0.8%) and BABA (-0.1%) saw declines.
Top Gainers: SHK PPT surged by 7.1% to a new high, followed by WUXI BIO (+5.1%) and CHINA SHENHUA (+4.0%), indicating strong performance among HSI and HSCEI constituents.
Significant Movements: Johnson Electric experienced a remarkable increase of 17.4%, while HAO TIAN INTL fell by 10.9%, highlighting volatility in smaller stocks.
Stock Performance: Several pharmaceutical stocks showed mixed performance, with HENGRUI PHARMA and HANSOH PHARMA experiencing gains, while SINO BIOPHARM saw a decline.
Short Selling Data: Short selling activity varied across companies, with SINO BIOPHARM having the highest short selling amount at $180.02M and a ratio of 40.682%.
Target Prices: Analysts have set target prices for various stocks, with HENGRUI PHARMA and HANSOH PHARMA rated as "Buy" with target prices of HK$98.3 and HK$51.5, respectively.
Market Sentiment: CSPC PHARMA received a "Neutral" rating, indicating a more cautious outlook compared to the "Buy" ratings for other companies listed.






